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ABSTRACT
Background: The type 2 deviated immunological state is predominant in lepromatous 
leprosy. Erythema nodosum leprosum (ENL) is an immune-complex mediated reaction 
that typically occurs in lepromatous leprosy. To date, the serum levels of tumor necrosis 
factor (TNF)-α, interleukin (IL)-2 receptor, IL-10, IL-1β, IL-1 receptor antagonist and 
monocyte chemoattractant protein-1 (MCP-1) were reported to be higher in lepromatous 
leprosy. TNF-α is also known to be higher in ENL, which is reduced after thalidomide 
treatment. However the serum type 2 chemokine levels in lepromatous leprosy patients 
have not been reported. Methods: The serum levels of the type 2 chemokines such 
as thymus and activation-regulated chemokine (TARC), macrophage-derived chemokine 
(MDC) and eotaxin together with IL-12 and IL-10 in the sera from leprosy patients 
were detected using an enzyme-linked solvent assay (ELISA) method. Results: The 
Serum TARC, MDC, eotaxin, IL-10 and IL-12 levels in lepromatous leprosy patients 
were not significantly different from the normal control levels. The serum levels were 
not significantly different between the paucibacillary group and multibacillary group. The 
serum TARC or MDC levels in the ENL patients were more reduced after a treatment 
containing thalidomide. Conclusion: The type 2 chemokines are not related to the 
severity of lepromatous leprosy. The larger reducing effect of the TARC or MDC levels 
in ENL patients by a treatment containing thalidomide suggests the potential role of 
these chemokines in the development of ENL and the therapeutic mechanism of 
thalidomide. (Immune Network 2002;2(4):223-226)
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Introduction
  Leprosy is a chronic infectious disease that is caused 
by a Mycobacterium leprae infection (1). Two polar types 
were initially classified by their clinical manifestations 
and response to lepromin (2). The molecular basis of 
these types has been explained by the differences in 
the cytokine expression in the lesions. Elevated 
interferon (IFN)-γ and interleukin (IL)-2 mRNA 
were reported in the tuberculoid leprosy lesions, but 
IL-4 and IL-10 mRNA are known to be elevated in 
the lepromatous leprosy lesions (3). Therefore, the 
type 2 deviated immunological state is predicted in 
lepromatous leprosy. The chemokines can be sub-
divided into type 1 and type 2 chemokines depending 
on the type of chemokine receptor expression in the 
Th1 and Th2 cells (4). Interferon-γ inducible protein- 
10 (IP-10), monokine induced by IFN-γ (Mig) and 
interferon-inducible T cell a chemoattractant (I-TAC), 
which all react with CXCR3, are believed to be type 
1 chemokines. Thymus and activation-regulated chemo-
kine (TARC) and macrophage-derived chemokine 
(MDC), which react with CCR4, and eotaxin, which 
reacts with CCR3, are all classed type 2 chemokines. 
Erythema nodosum leprosum (ENL) is an immune- 
complex mediated reaction that occurs typically in 
lepromatous leprosy (5). To date, the serum levels of 
tumor necrosis factor (TNF)-α, IL-2 receptor, IL-10, 
IL-1β, IL-1 receptor antagonist and monocyte che-
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Figure 1. The TARC, MDC, eotaxin, IL-10 and IL-12 serum levels in lepromatous leprosy patients with low BI (0～1, paucibacillary 
group, n=13) and high BI (2～4, multibacillary group, n=15) were compared with those from the healthy controls (n=14). The data 
is expressed as a mean±SD. BI, bacterial index.
moattractant protein-1 (MCP-1) were reported to be 
higher in lepromatous leprosy (6-9). However the 
changes in the serum type 2 chemokine levels in 
either lepromatous leprosy patients or ENL patients 
have not been reported. Therefore, in this study, the 
levels of several type 2 chemokines such as TARC, 
MDC and eotaxin together with those of IL-12 and 
IL-10 were examined.
Materials and Methods
  Twenty eight patients with leprosy (mean age; 50.6 
years, M：F=25：3 ) and 14 healthy controls (mean 
age; 42.8 years, M：F=1：13) were studied in Korea. 
The leprosy patients were all of the polar lepro-
matous (LL) type (10). The patients were divided into 
2 groups (paucibacillary versus multibacillary) based 
on the bacterial index (BI, 0～1 versus 2～4). The 
patients were composed of 13 (BI 1+), 6 (BI 2+), 
7 (BI 3+) and 2 (BI 4+) patients. The higher BI 
numbers represent the greater bacteria numbers (1+, 
1～10 bacteria in 100 fields; 2+, 1～10 bacteria in 
10 fields; 3+, 1～10 bacteria in an average field; 4+, 
10-100 bacteria in an average field; 5+, 100～1,000 
bacteria in an average field; 6+, ＞1,000 or many 
clumps of bacteria in an average field) in the tissue 
fluid from a slit-skin lesion smear, and these were 
counted in the oil-immersion fields by optical mi-
croscopy (11). The patients were treated with dap-
sone, rifampin and/or clofazimine. The other associ-
ated diseases in the patients were tuberculosis in 2 
patients, chronic hepatitis in 1 patient, chronic gas-
tritis in 1 patient, bone exposure in 1 patient and 
osteomyelitis in 1 patient. Patient 1 was a female 
lepromatous leprosy patient (BI 4+) who was di-
agnosed 30 years ago and treated with dapson, 
rifampicin and ofloxacin. An ENL reaction was 
suspected due to erythematous nodules on her face, 
which occurred after flu-like symptoms 10 days prior. 
Therefore, she was treated with rifampicin and 
dapson for 7 days, and simultaneously with predni-
solone (15 mg/day) for 2 days. The serum was then 
collected and treated with a starting dose of 100 mg/d 
thalidomide, which was then tapered to 50 mg/d and 
finally to 20mg/d for 4 weeks. Serum was collected 
after this treatment. She was also treated with oflo-
xacin (100 mg/d) and rifampicin (450 mg/d) during 
this period. Patient 2 was a male lepromatous leprosy 
patient (BI 4+ to 5+) who was diagnosed 17 years 
ago and treated with dapson, rifampicin and ofloxacin. 
An ENL reaction was suggested due to erythematous 
rashes and nodules on his body with flu-like symptom. 
Consequently, he was treated with thalidomide (100 
mg/d) for 7 days. Serum was then collected and he 
was treated with 100 mg/d thalidomide, which was 
tapered to 50 mg/d, which reduced to 20 mg/d, and 
finally to 10 mg/d for 4 weeks. Serum was collected 
after this treatment. He was also treated with dapson 
(100 mg/d) and rifampicin (450 mg/d) during this 
period of the ENL reaction and ofloxacin (200 mg/d) 
for 3 weeks. Blood samples were taken from the 
leprosy patients and the control group, which was 
then centrifuged at 4oC and stored at -70oC until 
required. A 96-well polystyrene microtiter plate coat-
ed with a murine monoclonal antibody against human 
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Figure 2. The change in TARC, MDC 
and eotaxin serum levels during an 
ENL reaction after a treatment con-
taining thalidomide. Patient 1 (A), 
patient 2 (B), TARC (￭-￭), MDC 
(▴-▴), eotaxin (•-•).
TARC (TECHNE Co. Minneapolis, MN, USA). The 
serum TARC levels were measured in the leprosy 
patients and the healthy controls according to a 
standard assay protocol. The serum MDC, eotaxin, 
IL-12, and IL-10 levels were also measured using an 
enzyme-linked solvent assay (ELISA) system for 
MDC, eotaxin, IL-12, and IL-10 (R&D Systems Inc. 
Minneapolis, MN, USA). Student's t test (two-tailed) 
was used for statistical analysis to determine the 
differences in each cytokines of the groups compared 
to the healthy control groups. A p value < 0.05 was 
considered significant.
Results
  The serum MDC, TARC, eotaxin, IL-10 and IL-12 
levels of either the lepromatous leprosy patients with 
high BI (2～4, multibacillary group) or the lepro-
matous leprosy patients with low BI (0～1, pauci-
bacillary group) were not significantly different from 
the normal control levels (P＞0.05) (Fig. 1A, 1B, 1C, 
1D, 1E). Among the serum levels of the chemokines 
tested, TARC (73% decrease in patient 1, 32% 
decrease in patient 2) level was shown to be the lowest 
after a treatment containing thalidomide. This was 
followed by MDC (15% decrease in patient 1, 41% 
decrease in patient 2) and eotaxin (5% decrease in 
patient 1, 20% decrease in patient 2) (Fig. 2).
Discussion
  The TARC, MDC, eotaxin, IL-12 and IL-10 serum 
levels in both the paucibacillary group and the 
multibacillary group of lepromatous leprosy patients 
were not significantly different from those of the 
normal control levels. However, increased serum 
IL-10 levels in both lepromatous leprosy patients and 
ENL patients were reported (6). This discrepancy in 
IL-10 appears to be due to the difference in the 
patient population, because the patients in this study 
were under treatment whereas in the previous report, 
the patients were untreated (6). In the ENL patients, 
the TARC serum levels in patient 1 and the MDC 
levels in patient 2 appeared to be lower than the 
other chemokines including eotaxin and MCP-1 (less 
than 17% suppression, data not shown) after 4-5 
weeks of a treatment containing thalidomide. The 
serum TNF-α levels were reported to be higher 
during the ENL reaction and were reduced by 
thalidomide treatment (12-14). Therefore, the current 
observation of the larger reducing effects on the 
TARC or MDC levels by a treatment containing 
thalidomide appear to be due to an indirect mecha-
nism through a reduction in the TNF-α levels, 
because both TARC and MDC are known to be 
induced by TNF-α (15,16). However, a direct effect 
of thalidomide on TARC and MDC is also possible 
considering that TNF-α can stimulate not only the 
production of TARC and MDC but also the pro-
duction of eotaxin (17). The larger reducing effect on 
the TARC or MDC levels in the ENL patients by 
a treatment containing thalidomide suggests a po-
tential role of these chemokines in the development 
of ENL and the therapeutic mechanism of thalid-
omide. The discrepancy in the reducing effect on 
TARC or MDC in these ENL patients cannot be 
explained, because the differential regulation of the 
production of these chemokines is unknown. However, 
since TARC and MDC react with the same receptor, 
it can be speculated that thalidomide has a greater 
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effect on the chemokine that reaches a higher level 
between TARC and MDC. In summary, it is believed 
that the type 2 chemokines are not related to the 
severity of lepromatous leprosy. It is speculated that 
TARC and MDC might play a role in the ENL 
pathogenesis, and thalidomide may exert its thera-
peutic effect by reducing the levels of these chemo-
kines.
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